

16 December 2015

Christine Chapman
Senior Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143

By email: christine.chapman@pharmac.govt.nz

Budesonide with eformoterol proposal

Dear Christine

The New Zealand Medical Association (NZMA) wishes to provide feedback on the above proposal.

We note that the proposal would remove the Special Authority relating to budesonide with eformoterol inhalers, and would also remove the restrictions for these combination inhalers on the Hospital Medicines List.

Single inhaler therapy with a long acting beta agonist and inhaled corticosteroid is the best modern treatment for patients with asthma. This proposal will improve patient access to single inhaler therapy. Accordingly, we are supportive of this proposal.

Yours sincerely



Ms Lesley Clarke
NZMA CEO